PT  - JOURNAL ARTICLE
AU  - Wajih Bukhari
AU  - Kerri M Prain
AU  - Patrick Waters
AU  - Mark Woodhall
AU  - Cullen M O‘Gorman
AU  - Laura Clarke
AU  - Roger A Silvestrini
AU  - Christine S Bundell
AU  - David Abernethy
AU  - Sandeep Bhuta
AU  - Stefan Blum
AU  - Mike Boggild
AU  - Karyn Boundy
AU  - Bruce J Brew
AU  - Matthew Brown
AU  - Wallace J Brownlee
AU  - Helmut Butzkueven
AU  - William M Carroll
AU  - Celia Chen
AU  - Alan Coulthard
AU  - Russell C Dale
AU  - Chandi Das
AU  - Keith Dear
AU  - Marzena J Fabis-Pedrini
AU  - David Fulcher
AU  - David Gillis
AU  - Simon Hawke
AU  - Robert Heard
AU  - Andrew P D Henderson
AU  - Saman Heshmat
AU  - Suzanne Hodgkinson
AU  - Sofia Jimenez-Sanchez
AU  - Trevor Killpatrick
AU  - John King
AU  - Christopher Kneebone
AU  - Andrew J Kornberg
AU  - Jeannette Lechner-Scott
AU  - Ming-Wei Lin
AU  - Christpher Lynch
AU  - Richard Macdonell
AU  - Deborah F Mason
AU  - Pamela A McCombe
AU  - Michael P Pender
AU  - Jennifer A Pereira
AU  - John D Pollard
AU  - Stephen W Reddel
AU  - Cameron Shaw
AU  - Judith Spies
AU  - James Stankovich
AU  - Ian Sutton
AU  - Steve Vucic
AU  - Michael Walsh
AU  - Richard C Wong
AU  - Eppie M Yiu
AU  - Michael H Barnett
AU  - Allan G Kermode
AU  - Mark P Marriott
AU  - John D E Parratt
AU  - Mark Slee
AU  - Bruce V Taylor
AU  - Ernest Willoughby
AU  - Robert J Wilson
AU  - Angela Vincent
AU  - Simon A Broadley
TI  - Incidence and prevalence of NMOSD in Australia and New Zealand
AID  - 10.1136/jnnp-2016-314839
DP  - 2017 Aug 01
TA  - Journal of Neurology, Neurosurgery & Psychiatry
PG  - 632--638
VI  - 88
IP  - 8
4099  - http://jnnp.bmj.com/content/88/8/632.short
4100  - http://jnnp.bmj.com/content/88/8/632.full
SO  - J Neurol Neurosurg Psychiatry2017 Aug 01; 88
AB  - Objectives We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry.Background NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established.Methods Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture–recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases.Results NMOSD was confirmed in 81/170 (48%) cases referred. Capture–recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD.Conclusions NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.